SQUILLACE, NICOLA
 Distribuzione geografica
Continente #
NA - Nord America 4.443
AS - Asia 2.496
EU - Europa 2.376
SA - Sud America 541
AF - Africa 56
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 5
Totale 9.922
Nazione #
US - Stati Uniti d'America 4.334
SG - Singapore 891
CN - Cina 539
IT - Italia 506
RU - Federazione Russa 438
BR - Brasile 424
HK - Hong Kong 423
DE - Germania 404
SE - Svezia 307
VN - Vietnam 297
IE - Irlanda 253
GB - Regno Unito 124
ID - Indonesia 115
CA - Canada 76
UA - Ucraina 70
IN - India 62
FI - Finlandia 48
AR - Argentina 46
DK - Danimarca 42
NL - Olanda 34
PL - Polonia 32
AT - Austria 29
KR - Corea 29
ZA - Sudafrica 28
JP - Giappone 25
BD - Bangladesh 24
FR - Francia 23
MX - Messico 23
EC - Ecuador 19
BE - Belgio 15
CO - Colombia 14
IQ - Iraq 13
TR - Turchia 13
CH - Svizzera 10
PK - Pakistan 10
PY - Paraguay 10
CL - Cile 9
ES - Italia 9
LT - Lituania 8
PE - Perù 8
KE - Kenya 7
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
MY - Malesia 6
AZ - Azerbaigian 5
CR - Costa Rica 5
EG - Egitto 5
CZ - Repubblica Ceca 4
IR - Iran 4
KZ - Kazakistan 4
PH - Filippine 4
SA - Arabia Saudita 4
SN - Senegal 4
TN - Tunisia 4
UZ - Uzbekistan 4
BG - Bulgaria 3
BY - Bielorussia 3
EU - Europa 3
IL - Israele 3
MA - Marocco 3
MD - Moldavia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
TH - Thailandia 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AU - Australia 2
KH - Cambogia 2
LU - Lussemburgo 2
MM - Myanmar 2
NG - Nigeria 2
NO - Norvegia 2
PR - Porto Rico 2
AL - Albania 1
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
HR - Croazia 1
JO - Giordania 1
KG - Kirghizistan 1
MN - Mongolia 1
PA - Panama 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
Totale 9.922
Città #
Ann Arbor 926
Singapore 549
Hong Kong 423
Ashburn 386
Frankfurt am Main 288
Fairfield 281
New York 260
Dublin 244
Chandler 240
Wilmington 198
Houston 143
Woodbridge 142
Santa Clara 106
Milan 105
Seattle 105
Jakarta 104
Los Angeles 99
Princeton 91
Beijing 88
Ho Chi Minh City 86
Cambridge 75
Dallas 73
Hefei 68
Dearborn 56
The Dalles 56
Hanoi 54
Jacksonville 52
São Paulo 42
Dong Ket 41
Lawrence 41
Shanghai 41
Chicago 39
Altamura 38
Moscow 37
London 32
Guangzhou 30
Buffalo 29
Seoul 29
Nanjing 28
Rome 28
Nuremberg 26
San Diego 26
Ottawa 24
Tokyo 24
Rio de Janeiro 22
Helsinki 21
Johannesburg 21
Warsaw 21
Brooklyn 18
Fremont 18
Vienna 16
Boston 15
Amsterdam 14
Andover 14
Brussels 14
Council Bluffs 14
Munich 14
Denver 13
Falls Church 13
Boardman 12
Da Nang 12
Montreal 12
Poplar 12
Lappeenranta 11
Monza 11
Phoenix 11
Stockholm 11
Toronto 11
Changsha 10
Chennai 10
Curitiba 10
Pune 10
Salt Lake City 10
Lachine 9
Nanchang 9
Palermo 9
Atlanta 8
Biên Hòa 8
Edmonton 8
Elk Grove Village 8
Guayaquil 8
Hangzhou 8
Shenyang 8
Turin 8
Belo Horizonte 7
Bogotá 7
Brasília 7
Carate Brianza 7
Columbus 7
Jinan 7
Manchester 7
Naples 7
Santo André 7
Zurich 7
Casorate Primo 6
Dhaka 6
Florence 6
Guarulhos 6
Lima 6
Mexico City 6
Totale 6.451
Nome #
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 306
Caratteristiche di una coorte di pazienti con co-infezione HIV/HCV: i dati dell’Ambulatorio di Malattie Infettive dell’Ospedale San Gerardo di Monza 281
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 276
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 274
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 268
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 262
Brachial and central blood pressure in HIV-infected subjects 260
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 257
HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation 255
miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis 244
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 234
Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare 232
miRNA-218 targets lipin-1 and glucose transporter type 4 genes in 3T3-L1 cells treated with lopinavir/ritonavir 224
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 219
Therapy of Sars-Coronavirus-2 pneumonia: is there an optimal IL-6 cut-off for successful tocilizumab treatment? 216
Weight gain: A possible side effect of all antiretrovirals 215
A multidisciplinary approach to screen the post-COVID-19 conditions 213
Unmasking tuberculosis in the era of antiretroviral treatment 213
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 211
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 203
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances 198
Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti? 195
Arterial structure and function in AIDS patients: the impact of renal damage. 180
Ruolo delle strutture ambulatoriali extra-ospedaliere per pazienti con COVID-19: l’esperienza dell’Hotspot COVID di Monza. Role of outpatient facilities for patients with COVID-19: the experience of the COVID Hotspot in Monza. 174
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 171
The role for tocilizumab in covid-19 patients: Reflections on monza cohort data 163
Frailty and long-COVID: is COVID-19 responsible for a transition in frailty status among older adults who survived hospitalization for COVID-19? 161
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study 160
Fattori associati con il ricovero ospedaliero per COVID-19 in 80 pazienti HIV-positivi italiani. Factors associated with hospital admission for COVID-19 in 80 Italian HIV patients. 155
Is It Feasible to Impact on Smoking Habits in HIV-Infected Patients? Mission Impossible from the STOPSHIV Project Cohort 154
Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort 154
Early changes in adhesion molecules expression and endothelial function in patients initiating ART with Atazanavir or Lopinavir 146
Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study 145
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 144
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project 143
Factors Associated With Weight Gain in People Treated With Dolutegravir 141
Clusterization of co-morbidities and multi-morbidities among persons living with HIV: A cross-sectional study 140
Factors associated with hospital admission for COVID-19 in HIV patients 139
Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study 138
Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort 138
Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade 138
SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients 136
Arterial structural and functional effects of two different antiretroviral therapy protocol on naïve HIV-infected subjects 134
Safety and tolerability of Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project 133
Behavioural survey and street-based HIV and HCV rapid testing programme among transgender sex workers 129
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing? 128
Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens 127
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA) 126
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 125
Incident diabetes in course of antiretroviral therapy 125
Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: A cross-sectional study 123
Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project 117
Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study 114
Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity? 113
Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda 108
Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir 107
The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile 105
HIV and SARS-CoV-2 Co-Infection: What are the Risks? 97
Reversibility of Central Nervous System Adverse Events in Course of Art 96
Totale 10.283
Categoria #
all - tutte 39.930
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.930


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021844 0 0 0 0 0 175 126 139 94 117 61 132
2021/2022692 75 63 82 61 19 48 18 34 18 60 68 146
2022/20231.272 135 346 108 104 67 193 23 103 84 21 50 38
2023/20241.037 51 18 69 29 119 315 165 48 83 27 7 106
2024/20252.021 92 219 107 116 175 135 109 57 193 341 174 303
2025/20262.764 576 451 373 581 571 212 0 0 0 0 0 0
Totale 10.283